Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980961 | 0.84 | GRM5 (0.55) | GRM5 | |
| SCHEMBL980685 | 0.82 | GRM5 (0.61) | GRM5 | |
| SCHEMBL2175371 | 0.79 | GRM5 (0.41) | GRM5 | |
| SCHEMBL1024657 | 0.78 | GRM5 (0.60) | GRM5 | |
| SCHEMBL4711543 | 0.76 | GRM5 (0.67) | GRM5 | |
| SCHEMBL8299041 | 0.75 | IDO1 (0.53) | GRM5 | |
| SCHEMBL30873480 | 0.74 | GRM5 (0.55) | GRM5 | |
| SCHEMBL2010490 | 0.74 | GRM5 (0.49) | GRM5 | |
| SCHEMBL4153877 | 0.73 | GRM5 (1.00) | GRM5 | |
| SCHEMBL981316 | 0.73 | GRM5 (0.44) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964620-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1670784-B1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-1670784-B1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1831193-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-01-15 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452909-B2 | Imidazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1831193-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| US-7241760-B2 | Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241760-B2 | Central nervous system disorders; psycholgical disorders; antiepi;eptic agents; schizophrenia; Alzheimer's disease; cognition activators; analgesics | HOFFMANN-LA ROCHE INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1670784-A1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023795-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054686-A1 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2004111040-A1 | HETEROARYL-SUBSTITUTED IMDAZOLE DERIVATIVES AS GLUTAMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254179-A1 | Heteroaryl-substituted imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254179-A1 | Heteroaryl-substituted imidazole derivatives | GRIN2A, GRIN2B, GRIK5 | GRM5 4/4885 |
| US-20050054686-A1 | Imidazole derivatives | CHRM2, CHRM1, ARG1 | GRM5 758/4885 |
| US-20090018171-A1 | IMIDAZOLE DERIVATIVES | CHRM2, CHRM1, ARG1 | GRM5 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.